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Introduction: A recent large randomized controlled trial revealed
that patients with lung cancer with epidermal growth factor receptor
(EGFR) mutations had better prognoses when treated with the
EGFR-tyrosine kinase inhibitor, gefitinib, than with cytotoxic che-
motherapeutic agents. Lung cancer with EGFR mutations is highly
sensitive to EGFR-tyrosine kinase inhibitors. The previous trial
implied that EGFR mutations might be predictive of the response to
cytotoxic chemotherapy.
Methods: Forty-six tumor tissue specimens (32 adenocarcinomas
and 14 nonadenocarcinomas) were obtained from patients with lung
cancer who underwent surgical resection. EGFR mutations were
detected using polymerase chain reaction-invader assay. A histocul-
ture drug response assay was used as an in vitro drug sensitivity test.
The inhibition rates of cisplatin, docetaxel (DOC), vinorelbine, and
gemcitabine were measured.
Results: Sensitizing EGFR mutations were detected in samples
from 14 patients, all with adenocarcinomas. The inhibition rate of
cisplatin in tumors with EGFR mutations (group M) was 34.8 
15.5%, which was significantly lower (p 0.0153) than in wild-type
tumors (group W; 46.6  14.0%). The inhibition rate of DOC in
group M (18.8  13.4%) was also significantly lower (p  0.0051)
than in group W (35.4  19.1%). There were no significant differ-
ences in inhibition rates of gemcitabine and vinorelbine between
groups M and W. Inhibition rates of DOC were significantly lower
in group M (p  0.0256) than in group W (32.6  18.4) in samples
from patients with adenocarcinoma.
Conclusion: The histoculture drug response assay indicated that
lung cancers with EGFR mutations were less sensitive to DOC than
EGFR wild-type tumors.
Key Words: Anticancer drug sensitivity test, EGFR gene, histocy-
tochemistry, mutation, non-small cell lung cancer.
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Many molecular factors predictive of the response tochemotherapy in non-small cell lung cancer
(NSCLC) have recently been reported in large clinical
studies.1–3 ERCC1 is a well-known predictive factor in the
response to platinum-based chemotherapy.1 The JBR.10
study also revealed class III -tubulin as a predictive
marker for the response to vinorelbine (VNR),2 and RRM1
is known to be a good predictive marker for gemcitabine
(GEM).3
Epidermal growth factor receptor (EGFR) mutations
are important predictive markers for the response to EGFR-
tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and
erlotinib.4,5 The proliferation and survival of lung cancer cells
harboring EGFR mutations are strongly associated with the
signal transduction pathway initiated by the tyrosine kinase
domain of EGFR, and they differ from other populations of
lung cancer cells with wild-type EGFR. The response to
cytotoxic chemotherapeutic agents might thus also differ
between tumors with and without EGFR mutations.
The recent large randomized controlled INTEREST
study revealed that patients with lung cancer with EGFR
mutations treated with gefitinib had better response rates than
those treated with docetaxel (DOC).6 It is well known that
lung cancers with EGFR mutations are highly sensitive to
EGFR-TKIs.
The INTEREST trial also reported a greater response to
DOC in EGFR mutation-positive patients than in wild-type
EGFR patients,6 suggesting that the presence of EGFR mu-
tations could be a predictive factor for the response to
cytotoxic chemotherapeutic agents.
The histoculture drug response assay (HDRA) is a
representative in vitro drug response assay used to test anti-
cancer agents.7–9 Several clinical studies of colorectal and
gastric cancers have revealed that the inhibition rates ob-
tained using the HDRA are predictive of the clinical re-
sponses to chemotherapy.7 We recently reported that the
HDRA was also useful for predicting the response of NSCLC
to chemotherapy, mainly using resected surgical specimens
from patients with NSCLC.10 The purpose of this study was
to examine the results of the HDRA in lung cancer in relation
to EGFR mutation status, and to determine if EGFR mutation
status was a predictive factor for the response to cytotoxic
chemotherapeutic agents.
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MATERIALS AND METHODS
Forty-six tissue specimens were obtained from patients
with lung cancer who underwent surgical resection at our
institute. There were 26 men and 20 women, aged 69  9
years (range, 43–84 years). There were 32 adenocarcinomas,
9 squamous cell carcinomas, and 5 tumors of other histologic
types. EGFR mutations were evaluated using polymerase
chain reaction-invader assay.11
The HDRA was used as an in vitro drug sensitivity test,
as reported previously.10 The inhibition rates of cisplatin
(CDDP), DOC, VNR, and GEM were measured in each
specimen. Collagen sponge gels manufactured from pig skin
were purchased from Sumitomo Medical, Japan. Tumor spec-
imens were minced into pieces weighing approximately 10
mg and then placed on prepared collagen surfaces in 24-well
microplates. Plates were incubated for 7 days at 37°C in the
presence of each drug, dissolved in RPMI 1640 medium
containing 20% fetal calf serum. They were left in a humid-
ified atmosphere containing 95% air/5% CO2. The concen-
trations of CDDP, DOC, VNR, and GEM were 20, 100, 40,
and 1000 g/ml, respectively.
After histoculture, 100 l Hanks Balanced Salt Solu-
tion containing 0.1 mg/ml type I collagenase (Sigma, Japan)
and 100 l 3-(4,5-dimetylthiazol-2-yl)-2,5-diphenyl tetrazo-
lium bromide solution in 5 mg/ml phosphate buffer solution
was added to each culture well and incubated for a further 16
hours. After extraction with dimethylsulfoxide, absorbance of
the solution in each well was read at 540 nm (control: 630 nm)
using a microplate reader (model 680, Bio-Rad, CA). Absor-
bance per gram of cultured tumor tissue (OD/W) was calculated
from the mean absorbance of tissues from four culture wells.
The tumor-tissue weight was determined before culture.
The inhibition rate was calculated using the following
formula:
Inhibition rate (%)  (1  mean OD/W of treated well/
mean OD/W of control well)  100.
The HDRA was regarded as evaluable when the mean
absorbance at 540 nm of extracted formazan from the control
tumor was 15/g. When the inhibition rate of the drug was
negative, it was regarded as zero, which represented no
chemosensitivity.
This study was approved by our Institutional Review
Board for Clinical Practice, and written informed consent was
obtained from all patients.
Statistical Analysis
All values are reported as mean  standard deviation.
Analysis of variance and 2 tests were used to evaluate the
significance of differences between the groups. A value of p
less than 0.05 indicated statistical significance.
RESULTS
Sensitizing EGFR mutations were detected in 14 pa-
tients, all with adenocarcinomas. The types of EGFR muta-
tions are listed in Table 1. The patient characteristics associ-
ated with the EGFR mutations are summarized in Table 2.
The wild-type EGFR group (group W) contained more pa-
tients with histologically aggressive tumor types and ad-
vanced-stage disease compared with patients with EGFR
mutations (group M).
HDRA data were available for CDDP, DOC, GEM, and
VNR in 45, 46, 34, and 41 patients, respectively. Several
specimens were not large enough to test all drugs. The
inhibition rates of CDDP, DOC, GEM, and VNR were
42.9  13.5%, 30.4  16.4%, 24.8  11.2%, and 23.2 
11.8%, respectively. The distribution of inhibition rates of
each drug is illustrated in Figure 1.
The inhibition rate of CDDP in group M was 34.8 
15.5%, which was significantly lower (p  0.0153) than that in
group W (46.6  14.0%). The inhibition rate of DOC in group
M (18.8  13.4%) was also significantly lower (p  0.0051)
than in group W (35.4  19.1%). The inhibition rates of GEM
were 21.2 11.9% and 25.7 12.4% and those for VNR were
21.7  18.4% and 23.9  17.3%, in groups M and W, respec-
tively. There were no significant differences in inhibition rates
between the two groups for GEM and VNR (Table 3).
The inhibition rate of CDDP in group W was higher
(p  0.0003) in nonadenocarcinoma patients (56.3  14.0%)
than in adenocarcinoma patients (39.5  9.1%), and the
inhibition rate was significantly higher in nonadenocarcino-
mas in group W than in group M (p  0.0009). However,
when inhibition rates of CDDP were compared within ade-
nocarcinoma patients, there was no significant difference
between the groups. There was no significant difference in
inhibition rates for DOC in group W between nonadenocar-
cinoma and adenocarcinoma patients (39.1  20.0% and
32.6  18.4%, respectively). The inhibition rates of DOC in
group M were significantly lower in both nonadenocarcinoma
(p  0.004) and adenocarcinoma (p  0.0256) patients,
compared with group W (Table 3).
DISCUSSION
No previous studies have reported on the relationship
between EGFR mutation status and the results of a chemo-
sensitivity test in NSCLC. However, several studies have
compared the clinical responses with chemotherapy between
EGFR-mutated and wild-type patients.6,12–14
The INTEREST trial was a phase III study that directly
compared gefitinib and DOC as a second-line therapy for
advanced NSCLC. Comparing the responses of EGFR-mu-
TABLE 1. Type of Epidermal Growth Factor Receptor
Mutation
Exons Type of Mutation n
18 G719S 2
19 E746-A750 del type 1 1
E746-A750 del type 2 2
E746-S752 del ins V 1
L747-A750 del ins P 1
L747-T751 del 2
20 S786Ia 1
21 L858R 5
a Additional mutation was observed in a case with mutation G719S.
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tated and wild-type patients to DOC was not the purpose of
their study but their data nevertheless allowed such a com-
parison to be made.6 The objective response rate for DOC
was 21.1% in patients with EGFR-mutated tumors and 9.8%
in patients with wild-type EGFR. However, the statistical
significance of this result was not reported.
Wu et al.12 investigated the associations between tumor
tissue EGFR mutations and response to front-line chemother-
apy and prognosis in 145 patients with advanced NSCLC.
The response rate in carriers of EGFR mutations was 34.5%,
which was similar to the 33.3% in wild-type EGFR carriers
(p  0.881). They concluded that EGFR mutations did not
influence the response to front-line chemotherapy in Chinese
patients with advanced NSCLC. They also suggested that
EGFR mutations were an independent prognostic factor in
Chinese patients with advanced NSCLC.
Kalikaki et al.13 also investigated 162 patients with
locally advanced/metastatic NSCLC who received front-line
FIGURE 1. Distribution of inhibi-
tion rates for each drug. CDDP,
cisplatin; DOC, docetaxel; GEM,
gemcitabine; VNR, vinorelbine.
TABLE 2. EGFR Mutation and Clinical Characteristics of Patients
Total Group M Group W pa
No. of patients 46 14 32
Age, yr (range) 69  9 (43–84) 67  9 (43–76) 70  9 (54–84) 0.2911
Gender
Male 26 6 20 0.333
Female 20 8 12
Histology
Adenocarcinoma 32 14 18 0.0038
Nonadenocarcinoma 14 0 14
p-stage
IA 20 8 12 0.0406b
IB 9 4 5
IIA 6 2 4
IIB 2 0 2
IIIA 6 0 6
IIIB 0 0 0
IV 3 0 3
a EGFR mutation (M) vs EGFR wild-type (W).
b Stage was divided into two groups for statistical analysis: early-stage disease (IA–IIB) and advanced-stage disease
(IIIA–IV).
EGFR, epidermal growth factor receptor.
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chemotherapy. Patients with classical EGFR mutations had a
higher probability of response to front-line chemotherapy
compared with those with wild-type EGFR (p  0.023).
Multivariate analysis showed that the presence of activating
EGFR mutations was an independent factor associated with
the response to front-line chemotherapy.
The response to second-line chemotherapy after first-
line EGFR-TKI therapy has also been reported. Wu et al.14
investigated 195 patients with stage IIIb or IV NSCLC who
received first-line gefitinib followed by at least one subse-
quent line of therapy. They reported that second-line therapy
with a platinum-based combination or a taxane-containing
regimen was associated with a higher response rate. These
studies suggest that EGFR mutations may be a predictive
marker when deciding on cytotoxic chemotherapy protocols
for patients with NSCLC. The response appeared to depend
on the type of mutation and the chemotherapy protocol used.
EGFR mutations play a further prognostic role in
NSCLC. Most of the studies mentioned earlier in the text also
reported a better prognosis in patients with EGFR mutations
compared with patients with wild-type EGFR.6,12,13 Most
researchers attributed this to a better response to chemother-
apy in tumors with EGFR mutations. Liu et al.15 investigated
the EGFR mutation status in 164 patients with surgically
resectable NSCLC. The median survival was much longer for
patients with EGFR mutations (54.7 months) compared with
wild-type EGFR (34.9 months). This difference demonstrated
borderline significance with multivariate analyses (p 
0.0506). In addition, the 3-year survival rates of patients with
EGFR mutations were also significantly higher than in those
with wild-type EGFR (p  0.0232). They concluded that
NSCLC patients with EGFR mutations had better survival
than those with wild-type EGFR. These results implied that
the presence of an EGFR mutation in itself is a positive
prognostic factor for NSCLC. In this study, patients with
wild-type EGFR status had aggressive histology and more
advanced-stage disease than those with EGFR mutations.
Most molecular predictive markers for the response to
chemotherapy also seem to be related to patient prognosis.
High levels of ERCC1 expression are known to be associated
with longer survival in patients with completely resected lung
cancer and are also associated with a poorer response to
platinum-based chemotherapy in patients with advanced lung
cancer.1 It is also known that high levels of class III -tubulin
expression are associated with both poor prognosis and a
good response to VNR.2
However, when a possible predictive marker for che-
motherapy response is also associated with patient prognosis,
it is not easy to prove its role as a predictive marker. For
example, a good prognosis is commonly associated with slow
growing tumors; a chemotherapeutic response tends to be
considered to be better when the tumor is slow growing, even
when the molecular marker is not associated with chemotherapy
response. A poor prognosis is commonly associated with ag-
gressive tumors; a chemotherapeutic response tends to be judged
to be ineffective, even when the chemotherapy significantly
inhibits tumor growth compared with nontreatment of tumors.
Se`ve et al.16 examined the expression of microtubular
components in 93 tumor samples from patients with advanced
NSCLC who received VNR-based chemotherapy. The re-
sponse rate to VNR-based chemotherapy, progression-free
survival, and overall survival was correlated with the expres-
sion of microtubule proteins. Class III -tubulin expression
was independently correlated with progression-free survival
and overall survival. They concluded that a high level of
expression of class III -tubulin in tumor cells was associated
with resistance to VNR and a poor prognosis. However,
analysis of the JBR.10 study results revealed that a high level
of class III -tubulin expression was associated with poor
prognosis and a good response to VNR.2 We have reported that
a high level of class III -tubulin expression is associated with
high inhibition rates for VNR in HDRA.17 Our results suggested
that the inconsistency of the results between these studies seems
to be caused by a high level of expression of class III -tubulin
acting as a strong negative prognostic factor.
To determine whether a marker is predictive or prog-
nostic, it is necessary to compare nontreated control groups
and treated groups in both marker negative and positive
patients, i.e., four groups need to be compared. The IALT and
JBR.10 studies satisfied this requirement because they were
phase III studies for adjuvant chemotherapy, with “surgery
only” control arms.1,2
Best supportive care is not currently a standard therapy
for NSCLC, and it is not considered to be ethically acceptable
to plan clinical randomized trials containing a best supportive
care arm for patients with NSCLC.
In vitro chemosensitivity tests such as the HDRA seem to
be a suitable means of overcoming this limitation. The inhibition
TABLE 3. Inhibition Rates and EGFR Mutation
Drugs
Inhibition Rate (%)
Group M
Group W
Total Adenocarcinoma Nonadenocarcinoma
CDDP 34.8  15.5 46.6  14.0a 39.5  9.1 56.3  14.0a
DOC 18.8  13.4 35.4  19.1a 32.6  18.4a 39.1  20.0a
GEM 21.2  11.9 25.7  12.4 25.8  13.1 25.6  12.1
VNR 21.7  18.4 23.9  17.3 23.0  14.2 25.0  20.9
a Statistically significant compared with Group M.
EGFR, epidermal growth factor receptor; CDDP, cisplatin; DOC, docetaxel; GEM, gemcitabine; VNR, vinorelbine.
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rate in HDRA is based on tumor viability in the treated tumor
compared with the nontreated tumor. The nontreated tumor in
HDRA is equivalent to a best supportive care arm in a clinical
trial. HDRA can therefore evaluate the chemosensitivity of
tumors independent of their aggressiveness.
We have mainly used the HDRA for resectable NSCLC
since 1994. It has shown high evaluability of 97.4% and good
predictability for clinical response with a positive predictive
value of 73.2%, a negative predictive value of 100%, and an
accuracy of 83.0%.10 It has recently been reported that
HDRA is also useful for predicting the efficacy of adjuvant
chemotherapy in NSCLC.18
We have reviewed the consistency of many well-known
predictive factors and the HDRA results of CDDP, paclitaxel,
DOC, VNR, and gefitinib in a number of studies.17,19–23 The
inhibition rate for CDDP in HDRA was well correlated with
the ERCC1 expression level in NSCLC.19 Similar results
were reported by another group using a different chemosen-
sitivity assay method.24 As for DOC, the inhibition rate was
significantly correlated with class III -tubulin expression of
the tumor.20 The HDRA seems to be appropriate for evalu-
ating predictive markers for chemotherapy in NSCLC.
The results of this study using HDRA revealed that the
chemosensitivities to CDDP and DOC were lower in tumors
with EGFR mutations compared with tumors with wild-type
EGFR. This result is inconsistent with those of the clinical
studies mentioned earlier in the text.6,12–14 However, these pre-
vious clinical studies did not contain a nontreated control arm,
and the results were therefore likely to be affected by the poor
prognosis of patients with tumors harboring wild-type EGFR.
In this study, patients with wild-type EGFR harbored
tumors with aggressive histologic types, such as squamous
cell and combined small cell lung cancer. In contrast, all
tumors with EGFR mutations were adenocarcinomas. When
the inhibition rates were compared within patients with ade-
nocarcinomas, there was no significant difference in inhibi-
tion rate for CDDP between tumors with mutated and wild-
type EGFR. However, the inhibition rate for DOC in patients
with EGFR mutations was still significantly lower than in
those with wild-type EGFR.
We conclude that the presence of EGFR mutations is
associated with resistance to DOC in patients with NSCLC,
independent of the role of EGFR mutation as a prognostic
factor. EGFR mutation status is now routinely measured in
clinical practice in patients with NSCLC. The results of this
study provide information that will aid in the choice of
suitable chemotherapeutic agents for patients with NSCLC.
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